Navigation Links
Human Genome Sciences Advances Oncology Portfolio
Date:4/16/2008

hts to its TRAIL receptor antibodies, HGS has agreed to a reduction in the royalties to which it is entitled from GSK if Syncria is commercialized. The fees and milestone payments due to HGS under the original Syncria agreement, some of which have already been received, could amount to as much as $183 million and remain unchanged in the amended agreement. Syncria, a novel long-acting form of GLP-1 (glucagon-like peptide-1), was created by HGS using its proprietary albumin-fusion technology. GSK has exclusive rights to develop and commercialize Syncria, and is developing it for use in the treatment of type 2 diabetes. HGS believes it is possible that GSK will reach a decision in 2008 regarding whether to advance Syncria to Phase 3 development.

"We view our oncology portfolio as the cornerstone of our mid-stage pipeline, and as a key driver of future growth beyond the launch of our late- stage products," said Barry A. Labinger, Executive Vice President and Chief Commercial Officer, HGS. "Reacquiring the rights to our TRAIL antibodies gives us the opportunity to drive and advance this growing program. We will continue to explore the possibility of bringing in additional new products, as well as forming new partnerships to add expertise and near-term financial resources in support of our pipeline."

HGS reported that a 2002 agreement with the Pharmaceutical Division of Kirin Brewery Company, Ltd. for joint development of antibodies to TRAIL receptor 2 has also been terminated.

About the HGS-ETR1 Proof-of-Concept Program

HGS-ETR1 is the most advanced of any product in development that targets the TRAIL apoptosis pathway. HGS has advanced HGS-ETR1 to a proof-of-concept phase consisting of three randomized Phase 2 chemotherapy combination trials to evaluate its potential in the treatment of specific cancers:

-- HGS has completed the enrollment and initial dosing of 105 patients in

a randomized Phase 2 trial of HGS-ETR1 in c
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
(Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... 30, 2015 According to a new ... Trends & Forecasts (2015-2020), , published by Mordor Intelligence, the ... by the end of 2020, with North America ... than 40% of the global market size. The Global market ... of 13.7% during the period of (2015-2020).      ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... in Three Companies, PITTSBURGH, Aug. 21 ... putting the region,s life,sciences industry on a fast ... a total of $450,000 in three companies: Applied ... "PLSG is committed to identifying and making investments ...
... for ,Courage Under Fire, WORCESTER, Mass., Aug. ... ACTC) is proud to announced that Dr.,Robert Lanza, ... has been recognized for his research and contributions ... issue of PharmaVOICE (cover,story July/August issue). Dr. Lanza ...
... Designed to Increase Efficiency, MINNEAPOLIS, Aug. ... ), a leading provider of enterprise-wide advanced,visualization ... released its,next generation enterprise-wide advanced visualization and ... 4.0 and ViTALConnect(R) 4.1. This,comprehensive package offers ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 3Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 4
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... million years old give unprecedented insight into the evolutionary ... species-rich groups among the modern bony fishes. Researchers ... of Paleontology and Geobiology at the Department of Earth ... Germany have completed a comprehensive analysis of fish fossils ...
... neuroscientists from Canada and around the world are meeting ... Meeting will showcase the latest in research findings about ... understanding the disorders that affect them., "Canada is a ... the best of neuroscience research done here and around ...
... May 16, 2013 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... practises such as photographs, passwords and PIN ...
Cached Biology News:Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 37th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
X-gal,1g...
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
... Conjugation, Quantities to Kilograms, ... Special amino acids and their ... labeling AMC, aldehyde, CMK, Purity ... Chromogenic/Flurogenic Substrates, Solid Phase/Solution/Segment ...
... The Gla-type Osteocalcin EIA Kit is ... kit for quantitative determination of human ... cell culture supernatants, and other biological ... research use only. It is not ...
Biology Products: